Laura Ekblad
MD, PhD
positron emission tomography; Alzheimer´s Disease; Insulin resistance; cognition; memory disorders
Specialist in Geriatrics and Family Medicine. Senior researcher, Turku Alzheimer Imaging Group, Turku PET Centre.
My research focuses on early risk factors for memory disorders, especially Alzheimer´s disease. I am particularly interested in the associations between metabolic risk factors (insulin resistance, glucose intolerance, obesity) and cognitive decline.
Our lab uses multimodal neuroimaging (PET-imaging, MRI) combined with blood and CSF biomarkers and cognitive testing to explore the association between different risk factors and early cerebral changes of memory disorders.
I also run a project that examines possible cardiac side effects of anti-dementia agents in elderly memory clinic patients.
- Iäkkäiden muistisairaudet tarvitsevat erikoisosaajia (2022)
- Lääkärilehti
- Insulin Resistance and the Brain-Novel Insights Combining Metabolic Research and Neuroscience (2022)
- Metabolites
- Neuropsykologiset tehtäväsarjat Alzheimerin taudin prekliinisen vaiheen hienoisen kognitiivisen heikentymisen havaitsemisessa (2022)
- Duodecim
- Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum (2022)
- JAMA Neurology
- Association of Early β-Amyloid Accumulation and Neuroinflammation Measured With [11C]PBR28 in Elderly Individuals Without Dementia (2021)
- Neurology
- Brain Glucose Metabolism in Health, Obesity, and Cognitive Decline-Does Insulin Have Anything to Do with It? A Narrative Review (2021)
- Journal of Clinical Medicine
- Episodic memory and cortical amyloid pathology: PET study in cognitively discordant twin pairs (2021)
- Neurobiology of Aging
- Four subgroups based on tau levels in Alzheimer's disease observed in two independent cohorts (2021)
- Alzheimer's Research and Therapy
- Oral Glucose Tolerance Test Predicts Episodic Memory Decline: A 10-Year Population-Based Follow-up Study (2021)
- Diabetes Care
- Proteomic correlates of cortical thickness in cognitively normal individuals with normal and abnormal cerebrospinal fluid beta-amyloid1-42 (2021)
- Neurobiology of Aging



